Key facts
- It has raised $45.0M; the latest was Early Stage VC ($45.0M) in Jan 2025.
- Notable investors include Catalio Capital Management, Mayo Clinic, The Production Board, BEVC (Berkeley), Blue Venture Fund — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for PinkDx
- ·The full record, as it builds
Funding rounds
No funding rounds for PinkDx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PinkDx
Developer of a diagnostic platform designed for improving the detection of women's health conditions. The company's platform applies molecular testing and other advanced scientific approaches to identify gynecological cancers earlier, focuses on replacing invasive and painful diagnostic procedures with less burdensome alternatives, and supports clinicians with clearer answers when women present with vague or general symptoms, enabling healthcare providers to improve diagnostic outcomes and reduce delays in care for women across their health journey.
- Sector
- Healthcare
- HQ
- Daly City, CA, United States
- Founded
- 2022
- Employees
- 32
- Website
- pinkdx.com/
- Ownership
- Privately Held (backing)
PinkDx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PinkDx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PinkDx in its N-PORT filings yet. We sweep new filings monthly.